Ozapez Drug Interactions

Metabolism/Transport Effects: Substrates of CYP1A2, CYP2D6.
Avoid Concomitant Use: Aclidinium, Amisulpride, Azelastine (Nasal), Benzodiazepines, Cimetropium, Eluxadoline, Glucagon, Glycopyrrolate, Ipratropium, Levosulpiride, Metoclopramide, Nitroglycerin, Orphenadrine, Oxatomide, Oxomemazine, Paraldehyde, Piribedil, Potassium Chloride, Sulpiride, Thalidomide, Tiotropium, Umeclidinium.
The levels/effects of Olanzapine may be increased by: Abiraterone acetate, Acetylcholinesterase inhibitors, Aclidinium, Blood pressure lowering agents, Brimonidine, Cannabis, Chloral betaine, Chlormethiazole, Chlorphenesin, Carbamate, CYP1A2 inhibitors, Deferasirox, Dimethindene, Doxylamine, Dronabinol, Droperidol, Fluvoxamine, Hydroxyzine, Ipratropium, Kava kava, Lamotrigine, Lithium, Lofexidine, Magnesium sulfate, Methotrimeprazine, Mifepristone, Monocycline, Nabilone, Obeticholic acid, Oxatomide, Oxomemazine, Peginterferon Alfa-2b, Perampanel, Pramlintide, Rufinamide, Serotonin modulators, Sodium oxybate, Tapentadol, Tetrahydrocannabinol, Trimeprazine, Umeclidinium, Vemurafenib.
Olanzapine may increase the levels/effects of: Abobotulinumtoxin A, Ethyl Alcohol, Amisulpride, Analgesics (Opioid), Anticholinergic Agents, Azelastine (Nasal), Benzodiazepines, Blonanserin, Buprenorphine, Cimetropium, CloZAPine, CNS Depressants, Eluxadoline, Glucagon, Glycopyrrolate (Oral Inhalation), Highest Risk QTc-Prolonging Agents, HYDROcodone, Iohexol, Iomeprol, Iopamidol, Mequitazine, Methotrimeprazine, Methylphenidate, MetyroSINE, Mirabegron, Mirtazapine, Moderate Risk QTc-Prolonging Agents, Onabotulinumtoxin A, Orphenadrine, OxyCODONE, Paraldehyde, Potassium Chloride, Ramosetron, Rimabotulinumtoxin B, Selective Serotonin Reuptake Inhibitors, Serotonin Modulators, Sulpiride, Suvorexant, Thalidomide, Thiazide and Thiazide-Like Diuretics, Tiotropium, TiZANidine, Topiramate, Zolpidem.
The levels/effects of Olanzapine may be decreased by: Acetylcholinesterase inhibitors, Antihepaciviral combination products, Cannabis, CYP1A2 inducers, Cyproterone, Lithium, Piribedil, Ritonavir, Teriflunomide, Valproate products.
Olanzapine may decrease the levels/effects of: Acetylcholinesterase Inhibitors, Amphetamines, Antidiabetic Agents, Anti-Parkinson Agents (Dopamine Agonist), Gastrointestinal Agents (Prokinetic), Itopride, Levosulpiride, Nitroglycerin, Piribedil, Quinagolide, Secretin.
Anticholinergic Agents: Olanzapine should be used with caution in patients concurrently receiving other drugs with anticholinergic activity.
Levodopa and Dopamine Agonists: Olanzapine may antagonize the effects of levodopa and dopamine agonists.
Lamotrigine: Olanzapine did not substantially alter lamotrigine pharmacokinetics when the drugs were administered concurrently. The tolerability of this combination was found to be similar to that of olanzapine alone, with mild sedative effects reported in some patients receiving the drug concurrently. Adjustment in Lamotrigine dosage may be necessary in some patients for therapeutic reasons when olanzapine therapy is initiated or discontinued.
Other CNS-Active Agents: The concomitant use of olanzapine with CNS agents (e.g. diazepam) that are associated with hypotension may potentiate the orthostatic hypotension associated with olanzapine.
Alcohol: The concomitant use of olanzapine with alcohol potentiated the orthostatic hypotension associated with olanzapine. Therefore, states of alcohol should be avoided during olanzapine therapy.
Hypotensive Agents: Olanzapine therapy potentially may enhance the effects of certain hypotensive agents during concurrent use. In addition, the administration of dopamine, epinephrine, and/or other sympathomimetic agents with β-agonist activity should be avoided in the treatment of olanzapine-induced hypotension.
Activated Charcoal: Concurrent administration of activated charcoal reduced peak plasma concentrations of olanzapine by approximately 60%.
Smoking: Plasma olanzapine concentrations generally are lower in smokers than in non-smoker.